Advertisement

TLR Agonists as Vaccine Adjuvants

  • Mark A. TomaiEmail author
  • John P. Vasilakos
Chapter

Abstract

Despite the development of numerous successful vaccines, there are many pathogens for which a vaccine does not exist. In addition, it is clear that cancer vaccines will require novel adjuvants. Currently a number of non-live vaccines are being evaluated in order to address adverse events associated with live vaccines, however many of these have been proven to be ineffective. The major problem with most protein, peptide, and DNA vaccines is that they are poorly immunogenic or elicit an inappropriate immune response, and don’t provide protection against the infectious agent or cancers. Therefore novel adjuvants that boost the immune responses will be required to make these vaccines effective. Many of the effects induced through activation of toll-like receptors (TLRs) can have significant effects on adaptive immune responses. Since ligands have been identified for many TLRs, and activation of TLRs results in stimulation of antigen presenting cells and enhanced B cell and T cell activation, TLR agonists are considered promising vaccine adjuvant candidates. This chapter will focus on TLR agonists that are in development for use as vaccine adjuvants.

Keywords

Toll-like receptor TLR agonists Pathogen recognition receptor Pathogen associated molecular pattern Adjuvants Dendritic cells 

Notes

Acknowledgments

We thank Dr. Paul Wightman and David Brandwein for 3M-052 vaccine adjuvant data and for formulation and characterization of 3M-052 vaccine formulations and pharmacokinetic data.

References

  1. Adams S, O’Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, Shapiro RL, Berman RS, Berner N, Shao Y, Manches O, Pan L, Venhaus RR, Hoffman EW, Jungbluth A, Gnjatic S, Old L, Pavlick AC, Bhardwaj N (2008) Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181:776–784PubMedGoogle Scholar
  2. Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T, Pulendran B (2003) Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 171:4984–4989PubMedGoogle Scholar
  3. Ahmad G, Zhang W, Torben W, Noor Z, Siddiqui AA (2010) Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice. Int J Infect Dis 1:e781–e787Google Scholar
  4. Ahonen CL, Gibson SJ, Smith RM, Pederson LK, Lindh JM, Tomai MA, Vasilakos JP (1999) Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell Immunol 197:62–72PubMedGoogle Scholar
  5. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801PubMedGoogle Scholar
  6. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413:732–738PubMedGoogle Scholar
  7. Ballas ZK, Rasmussen WL, Krieg AM (1996) Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157:1840–1845PubMedGoogle Scholar
  8. Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, Ferreira LC, Soares IS, Costa FT, Rodrigues MM (2010) Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium. Vaccine 28:2818–2826PubMedGoogle Scholar
  9. Ben-Yedidia T, Arnon R (2006) Flagella as a platform for epitope-based vaccines. Isr Med Assoc J 8:316–318PubMedGoogle Scholar
  10. Blasius AL, Beutler B (2010) Intracellular toll-like receptors. Immunity 32:305–315PubMedGoogle Scholar
  11. Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM (2011) CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 10:499–511PubMedGoogle Scholar
  12. Bohnenkamp HR, Papazisis KT, Burchell JM, Taylor-Papadimitriou J (2007) Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. Cell Immunol 247:72–84PubMedGoogle Scholar
  13. Brugnolo F, Sampognaro S, Liotta F, Cosmi L, Annunziato F, Manuelli C, Campi P, Maggi E, Romagnani S, Parronchi P (2003) The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol 111:380–388PubMedGoogle Scholar
  14. Camacho AG, Teixeira LH, Bargieri DY, Boscardin SB, Soares Ida S, Nussenzweig RS, Nussenzweig V, Rodrigues MM (2011) TLR5-dependent immunogenicity of a recombinant fusion protein containing an immunodominant epitope of malarial circumsporozoite protein and the FliC flagellin of Salmonella Typhimurium. Mem Inst Oswaldo Cruz 106(Suppl 1):167–171PubMedGoogle Scholar
  15. Carmichael JR, Pal S, Tifrea D, de la Maza LM (2011) Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine. Vaccine 29:5276–5283PubMedGoogle Scholar
  16. Chang BA, Cross JL, Najar HM, Dutz JP (2009) Topical resiquimod promotes priming of CTL to parenteral antigens. Vaccine 27:5791–5799PubMedGoogle Scholar
  17. Cheng C, Jain P, Bettahi I, Pal S, Tifrea D, de la Maza LM (2011) A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors. Vaccine 29:6641–6649PubMedGoogle Scholar
  18. Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33:492–503PubMedGoogle Scholar
  19. Cooper C, Mackie D (2011) Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV safety and efficacy. Expert Rev Vaccines 10:417–427PubMedGoogle Scholar
  20. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J (2004) CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24:693–701PubMedGoogle Scholar
  21. Cui Z, Qiu F (2006) Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother 55:1267–1279PubMedGoogle Scholar
  22. Daifalla NS, Bayih AG, Gedamu L (2011) Immunogenicity of Leishmania donovani iron superoxide dismutase B1 and peroxidoxin 4 in BALB/c mice: the contribution of Toll-like receptor agonists as adjuvant. Exp Parasitol 129:292–298PubMedGoogle Scholar
  23. Davey GM, Wojtasiak M, Proietto AI, Carbone FR, Heath WR, Bedoui S (2010) Cutting edge: priming of CD8 T cell immunity to herpes simplex virus type 1 requires cognate TLR3 expression in vivo. J Immunol 184:2243–2246PubMedGoogle Scholar
  24. Davis HL, Suparto II, Weeratna RR, Jumintarto IDD, Chamzah SS, Ma’ruf AA, Nente CC, Pawitri DD, Krieg AM, Heriyanto SW, Sajuthi DD (2000) CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18:1920–1924PubMedGoogle Scholar
  25. Diebold SS (2008) Recognition of viral single-stranded RNA by Toll-like receptors. Adv Drug Deliv Rev 60:813–823PubMedGoogle Scholar
  26. Diebold SS, Massacrier C, Akira S, Paturel C, Morel Y, Reis e Sousa C (2006) Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur J Immunol 36:3256–3267PubMedGoogle Scholar
  27. Dory D, Beven V, Torche AM, Bougeard S, Cariolet R, Jestin A (2005) CpG motif in ATCGAT hexamer improves DNA-vaccine efficiency against lethal Pseudorabies virus infection in pigs. Vaccine 23:4532–4540PubMedGoogle Scholar
  28. Du J, Wu Z, Ren S, Wei Y, Gao M, Randolph GJ, Qu C (2010) TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity. Vaccine 28:6273–6281PubMedGoogle Scholar
  29. Durand V, Wong SY, Tough DF, Le Bon A (2004) Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol Cell Biol 82:596–602PubMedGoogle Scholar
  30. Duthie MS, Windish HP, Fox CB, Reed SG (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239:178–196PubMedGoogle Scholar
  31. Gautier G, Humbert M, Deauvieau F, Scuiller M, Hiscott J, Bates EE, Trinchieri G, Caux C, Garrone P (2005) A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 201:1435–1446PubMedGoogle Scholar
  32. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane SW, Noelle RJ, Miller RL, Kedl RM, Fitzgerald-Bocarsly P, Tomai MA, Vasilakos JP (2002) Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 218:74–86PubMedGoogle Scholar
  33. Gowen BB, Wong MH, Jung KH, Sanders AB, Mitchell WM, Alexopoulou L, Flavell RA, Sidwell RW (2007) TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules. J Immunol 178:5200–5208PubMedGoogle Scholar
  34. Gupta K, Cooper C (2008) A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R&D 9:137–145Google Scholar
  35. Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ (2003) A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21:2461–2467PubMedGoogle Scholar
  36. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM (2000) Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164:1617–1624PubMedGoogle Scholar
  37. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099–1103PubMedGoogle Scholar
  38. Heil F, Ahmad-Nejad P, Hemmi H, Hochrein H, Ampenberger F, Gellert T, Dietrich H, Lipford G, Takeda K, Akira S, Wagner H, Bauer S (2003) The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 33:2987–2997PubMedGoogle Scholar
  39. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408:740–745PubMedGoogle Scholar
  40. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196–200PubMedGoogle Scholar
  41. Hengge UR, Ruzicka T (2004) Topical immunomodulation in dermatology: potential of toll-like receptor agonists. Dermatol Surg 30:1101–1112PubMedGoogle Scholar
  42. Hong SH, Byun YH, Nguyen CT, Kim SY, Seong BL, Park S, Woo GJ, Yoon Y, Koh JT, Fujihashi K, Rhee JH, Lee SE (2012) Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine 30:466–474PubMedGoogle Scholar
  43. Honko AN, Sriranganathan N, Lees CJ, Mizel SB (2006) Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 74:1113–1120PubMedGoogle Scholar
  44. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G (2002) Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168:4531–4537PubMedGoogle Scholar
  45. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, Umlauf S, Tussey L, Powell TJ (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26:201–214PubMedGoogle Scholar
  46. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura SI, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H (2005) Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79:2910–2919PubMedGoogle Scholar
  47. Igartua M, Pedraz JL (2010) Topical resiquimod: a promising adjuvant for vaccine development? Expert Rev Vaccines 9:23–27PubMedGoogle Scholar
  48. Imanishi T, Hara H, Suzuki S, Suzuki N, Akira S, Saito T (2007) Cutting edge: TLR2 directly triggers Th1 effector functions. J Immunol 178:6715–6719PubMedGoogle Scholar
  49. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A (2001) Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 31:3388–3393PubMedGoogle Scholar
  50. Johnson AG, Gaines S, Landy M (1956) Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide. J Exp Med 103:225–246PubMedGoogle Scholar
  51. Johnson TR, Rao S, Seder RA, Chen M, Graham BS (2009) TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine 27:3045–3052PubMedGoogle Scholar
  52. Jones TR, Obaldia N 3rd, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, Davis HL, Krieg AM, Hoffman SL (1999) Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 17:3065–3071PubMedGoogle Scholar
  53. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V, Vulink AJ, Hart DN, Radford KJ (2010) Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 207:1247–1260PubMedGoogle Scholar
  54. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S (2002) Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 3:499PubMedGoogle Scholar
  55. Kadowaki N, Ho S, Antonenko S, De Waal MR, Kastelein RA, Bazan F, Liu YJ (2001) Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194:863–869PubMedGoogle Scholar
  56. Kaisho T, Akira S (2003) Regulation of dendritic cell function through Toll-like receptors. Curr Mol Med 3:373–385PubMedGoogle Scholar
  57. Kastenmuller K, Wille-Reece U, Lindsay RW, Trager LR, Darrah PA, Flynn BJ, Becker MR, Udey MC, Clausen BE, Igyarto BZ, Kaplan DH, Kastenmuller W, Germain RN, Seder RA (2011) Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J Clin Invest 121:1782–1796PubMedGoogle Scholar
  58. Klinman DM (2003) CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2:305–315PubMedGoogle Scholar
  59. Krieg AM (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5:471–484PubMedGoogle Scholar
  60. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546–549PubMedGoogle Scholar
  61. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G (2001) Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 31:2154–2163PubMedGoogle Scholar
  62. Lai Z, Schreiber JR (2011) Outer membrane protein complex of meningococcus enhances the antipolysaccharide antibody response to pneumococcal polysaccharide-CRM197 conjugate vaccine. Clin Vaccine Immunol 18:724–729PubMedGoogle Scholar
  63. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, Borrow P, Tough DF (2003) Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4:1009–1015PubMedGoogle Scholar
  64. Lee JW, Lin YM, Yen TY, Yang WJ, Chu CY (2010) CpG oligodeoxynucleotides containing GACGTT motifs enhance the immune responses elicited by a goose parvovirus vaccine in ducks. Vaccine 28:7956–7962PubMedGoogle Scholar
  65. Leelawongtawon R, Somroop S, Chaisri U, Tongtawe P, Chongsa-nguan M, Kalambaheti T, Tapchaisri P, Pichyangkul S, Sakolvaree Y, Kurazono H, Hayashi H, Chaicumpa W (2003) CpG DNA, liposome and refined antigen oral cholera vaccine. Asian Pac J Allergy Immunol 21:231–239PubMedGoogle Scholar
  66. Liang S, Hosur KB, Nawar HF, Russell MW, Connell TD, Hajishengallis G (2009) In vivo and in vitro adjuvant activities of the B subunit of Type IIb heat-labile enterotoxin (LT-IIb-B5) from Escherichia coli. Vaccine 27:4302–4308PubMedGoogle Scholar
  67. Linghua Z, Xingshan T, Fengzhen Z (2006) The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo. Int Immunopharmacol 6:1267–1276PubMedGoogle Scholar
  68. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K (1997) CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol 27:2340–2344PubMedGoogle Scholar
  69. Liu G, Tarbet B, Song L, Reiserova L, Weaver B, Chen Y, Li H, Hou F, Liu X, Parent J, Umlauf S, Shaw A, Tussey L (2011) Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS One 6:e20928PubMedGoogle Scholar
  70. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinman RM (2009) Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206:1589–1602PubMedGoogle Scholar
  71. Lore K, Betts MR, Brenchley JM, Kuruppu J, Khojasteh S, Perfetto S, Roederer M, Seder RA, Koup RA (2003) Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol 171:4320–4328PubMedGoogle Scholar
  72. Lousada-Dietrich S, Jogdand PS, Jepsen S, Pinto VV, Ditlev SB, Christiansen M, Larsen SO, Fox CB, Raman VS, Howard RF, Vedvick TS, Ireton G, Carter D, Reed SG, Theisen M (2011) A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 – A GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 29:3284–3292PubMedGoogle Scholar
  73. Ma R, Du JL, Huang J, Wu CY (2007) Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem Biophys Res Commun 361:537–542PubMedGoogle Scholar
  74. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P (2004) Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64:5934–5937PubMedGoogle Scholar
  75. Marshall-Clarke S, Downes JE, Haga IR, Bowie AG, Borrow P, Pennock JL, Grencis RK, Rothwell P (2007) Polyinosinic acid is a ligand for toll-like receptor 3. J Biol Chem 282:24759–24766PubMedGoogle Scholar
  76. McSorley SJ, Ehst BD, Yu Y, Gewirtz AT (2002) Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol 169:3914–3919PubMedGoogle Scholar
  77. Medvedev AE, Flo T, Ingalls RR, Golenbock DT, Teti G, Vogel SN, Espevik T (1998) Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-kappaB activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls. J Immunol 160:4535–4542PubMedGoogle Scholar
  78. Miller RL, Meng TC, Tomai MA (2008) The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect 21:69–87PubMedGoogle Scholar
  79. Mitchell MS (2003) Immunotherapy as part of combinations for the treatment of cancer. Int Immunopharmacol 3:1051–1059PubMedGoogle Scholar
  80. Moisan J, Camateros P, Thuraisingam T, Marion D, Koohsari H, Martin P, Boghdady ML, Ding A, Gaestel M, Guiot MC, Martin JG, Radzioch D (2006) TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway. Am J Physiol Lung Cell Mol Physiol 290:L987–L995PubMedGoogle Scholar
  81. Morse MA, Chapman R, Powderly J, Blackwell KL, Keler T, Green J, Riggs R, He L-Z, Ramakrishna V, Vitale L, Zhao B, Hobeika A, Osada T, Davis TA, Clay TM, Lyerly HK (2011) Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self antigens in cancer patients. Clin Cancer Res 17:4844–4853PubMedGoogle Scholar
  82. Moyle PM, Olive C, Ho MF, Good MF, Toth I (2006) Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation. J Med Chem 49:6364–6370PubMedGoogle Scholar
  83. Mullen GE, Ellis RD, Miura K, Malkin E, Nolan C, Hay M, Fay MP, Saul A, Zhu D, Rausch K, Moretz S, Zhou H, Long CA, Miller LH, Treanor J (2008) Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One 3:e2940PubMedGoogle Scholar
  84. Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S, Auray G, Eng N, Garlapati S, Babiuk LA, Potter A (2011) Combination adjuvants: the next generation of adjuvants? Expert Rev Vaccines 10:95–107PubMedGoogle Scholar
  85. Nair S, McLaughlin C, Weizer A, Su Z, Boczkowski D, Dannull J, Vieweg J, Gilboa E (2003) Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 171:6275–6282PubMedGoogle Scholar
  86. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6:769–776PubMedGoogle Scholar
  87. Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH (2011) Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine 29:5731–5739PubMedGoogle Scholar
  88. Nyirenda MH, Sanvito L, Darlington PJ, O’Brien K, Zhang GX, Constantinescu CS, Bar-Or A, Gran B (2011) TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J Immunol 187:2278–2290PubMedGoogle Scholar
  89. Otero M, Calarota SA, Felber B, Laddy D, Pavlakis G, Boyer JD, Weiner DB (2004) Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine 22:1782–1790PubMedGoogle Scholar
  90. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G (1995) MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 6:277–296PubMedGoogle Scholar
  91. Pantel A, Cheong C, Dandamudi D, Shrestha E, Mehandru S, Brane L, Ruane D, Teixeira A, Bozzacco L, Steinman RM, Longhi MP (2012) A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo. Eur J Immunol 42:101–109PubMedGoogle Scholar
  92. Payette PJ, Ma X, Weeratna RD, McCluskie MJ, Shapiro M, Engle RE, Davis HL, Purcell RH (2006) Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge. Intervirology 49:144–151PubMedGoogle Scholar
  93. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085–2088PubMedGoogle Scholar
  94. Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, Keller AM, Joffre O, Zelenay S, Nye E, Le Moine A, Faure F, Donckier V, Sancho D, Cerundolo V, Bonnet D, Reis e Sousa C (2010) Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 207:1261–1271PubMedGoogle Scholar
  95. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM (2006) The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 176:157–164PubMedGoogle Scholar
  96. Quarcoo D, Weixler S, Joachim RA, Stock P, Kallinich T, Ahrens B, Hamelmann E (2004) Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice. Clin Exp Allergy 34:1314–1320PubMedGoogle Scholar
  97. Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS (2010) Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 115:1949–1957PubMedGoogle Scholar
  98. Ramakrishna V, Vasilakos JP, Tario JD Jr, Berger MA, Wallace PK, Keler T (2007) Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J Transl Med 5:5PubMedGoogle Scholar
  99. Ren J, Sun L, Yang L, Wang H, Wan M, Zhang P, Yu H, Guo Y, Yu Y, Wang L (2010) A novel canine favored CpG oligodeoxynucleotide capable of enhancing the efficacy of an inactivated aluminum-adjuvanted rabies vaccine of dog use. Vaccine 28:2458–2464PubMedGoogle Scholar
  100. Roh HJ, Sung HW, Kwon HM (2006) Effects of DDA, CpG-ODN, and plasmid-encoded chicken IFN-gamma on protective immunity by a DNA vaccine against IBDV in chickens. J Vet Sci 7:361–368PubMedGoogle Scholar
  101. Sagara I, Ellis RD, Dicko A, Niambele MB, Kamate B, Guindo O, Sissoko MS, Fay MP, Guindo MA, Kante O, Saye R, Miura K, Long C, Mullen GE, Pierce M, Martin LB, Rausch K, Dolo A, Diallo DA, Miller LH, Doumbo OK (2009) A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine 27:7292–7298PubMedGoogle Scholar
  102. Salaun B, Greutert M, Romero P (2009) Toll-like receptor 3 is necessary for dsRNA adjuvant effects. Vaccine 27:1841–1847PubMedGoogle Scholar
  103. Salem ML, Kadima AN, Cole DJ, Gillanders WE (2005) Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother 28:220–228PubMedGoogle Scholar
  104. Salem ML, El-Naggar SA, Kadima A, Gillanders WE, Cole DJ (2006) The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 24:5119–5132PubMedGoogle Scholar
  105. Samulowitz U, Weber M, Weeratna R, Uhlmann E, Noll B, Krieg AM, Vollmer J (2010) A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. Oligonucleotides 20:93–101PubMedGoogle Scholar
  106. Sauder DN, Smith MH, Senta-McMillian T, Soria I, Meng TC (2003) Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob Agents Chemother 47:3846–3852PubMedGoogle Scholar
  107. Schulke S, Burggraf M, Waibler Z, Wangorsch A, Wolfheimer S, Kalinke U, Vieths S, Toda M, Scheurer S (2011) A fusion protein of flagellin and ovalbumin suppresses the T(H)2 response and prevents murine intestinal allergy. J Allergy Clin Immunol 128:1340–1348 e1312PubMedGoogle Scholar
  108. Schulz O, Diebold SS, Chen M, Näslund TI, Nolte MA, Alexopoulou L, Azuma YT, Flavell RA, Liljeström P, Reis E, Sousa C (2005) Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433:887–892PubMedGoogle Scholar
  109. Siegrist CA, Pihlgren M, Tougne C, Efler SM, Morris ML, AlAdhami MJ, Cameron DW, Cooper CL, Heathcote J, Davis HL, Lambert PH (2004) Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 23:615–622PubMedGoogle Scholar
  110. Singh M, Ugozzoli M, Kazzaz J, Chesko J, Soenawan E, Mannucci D, Titta F, Contorni M, Volpini G, Del Guidice G, O’Hagan DT (2006) A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 24:1680–1686PubMedGoogle Scholar
  111. Slutter B, Bal SM, Ding Z, Jiskoot W, Bouwstra JA (2011) Adjuvant effect of cationic liposomes and CpG depends on administration route. J Control Release 154:123–130PubMedGoogle Scholar
  112. Smirnov D, Schmidt JJ, Capecchi JT, Wightman PD (2011) Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29:5434–5442PubMedGoogle Scholar
  113. Sogaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, Davis HL, Schonheyder HC, Ostergaard L (2010) Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 51:42–50PubMedGoogle Scholar
  114. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115:739–746PubMedGoogle Scholar
  115. Stahl-Hennig C, Eisenblätter M, Jasny E, Rzehak T, Tenner-Racz K, Trumpfheller C, Salazar AM, Überla K, Nieto K, Kleinschmidt J, Schulte R, Gissmann LM, Müller M, Sacher A, Racz P, Steinman RM, Uguccioni M, Ignatius R (2009) Synthetic double-stranded RNAs are adjuvants for the induction of t helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 5(4)Google Scholar
  116. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, Miller RL, Sauder DN (2000) Imiquimod, a topical immune response modifier, induces migxration of Langerhans cells. J Invest Dermatol 114:135–141PubMedGoogle Scholar
  117. Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, Ozer K, Tussey L, Shaw A (2011) Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 29:4897–4902PubMedGoogle Scholar
  118. Thomann JS, Heurtault B, Weidner S, Braye M, Beyrath J, Fournel S, Schuber F, Frisch B (2011) Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting. Biomaterials 32:4574–4583PubMedGoogle Scholar
  119. Thomas LJ, Hammond RA, Forsberg EM, Geoghegan-Barek KM, Karalius BH, Marsh HC Jr, Rittershaus CW (2008) Co-administration of a CpG adjuvant (VaxImmune(trade mark), CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice. Hum Vaccin 5:79–84Google Scholar
  120. Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP (2004) Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22:1799–1809PubMedGoogle Scholar
  121. Tokunaga T, Yamamoto T, Yamamoto S (1999) How BCG led to the discovery of immunostimulatory DNA. Jpn J Infect Dis 52:1–11PubMedGoogle Scholar
  122. Tomai MA, Solem LE, Johnson AG, Ribi E (1987) The adjuvant properties of a nontoxic monophosphoryl lipid A in hyporesponsive and aging mice. J Biol Response Mod 6:99–107PubMedGoogle Scholar
  123. Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ (2000) The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 203:55–65PubMedGoogle Scholar
  124. Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, Fitzgerald T, Liu G, Kavita U, Song L, Dark I, Shaw A (2010) Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28:8268–8274PubMedGoogle Scholar
  125. Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, Huang Y, Schlesinger SJ, Colonna M, Steinman RM (2008) The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 105:2574–2579PubMedGoogle Scholar
  126. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A (2011) Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29:5145–5152PubMedGoogle Scholar
  127. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O’Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, Angiulli F, Mears G, Vogel SM, Pan L, Jungbluth AA, Hoffmann EW, Venhaus R, Ritter G, Old LJ, Ayyoub M (2007) Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104:8947–8952PubMedGoogle Scholar
  128. Vasilakos JP, Smith RM, Gibson SJ, Lindh JM, Pederson LK, Reiter MJ, Smith MH, Tomai MA (2000) Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol 204:64–74PubMedGoogle Scholar
  129. Velasquez LS, Hjelm BE, Arntzen CJ, Herbst-Kralovetz MM (2010) An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin Vaccine Immunol 17:1850–1858PubMedGoogle Scholar
  130. Verthelyi D (2006) Adjuvant properties of CpG oligonucleotides in primates. Methods Mol Med 127:139–158PubMedGoogle Scholar
  131. Verthelyi D, Klinman DM (2003) Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol 109:64–71PubMedGoogle Scholar
  132. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM (2001) Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol 166:2372–2377PubMedGoogle Scholar
  133. Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM (2002) CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 168:1659–1663PubMedGoogle Scholar
  134. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM (2004) Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34:251–262PubMedGoogle Scholar
  135. Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B, Schmitt E, Schild H, Radsak MP (2006) Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108:544–550PubMedGoogle Scholar
  136. Wedlock DN, Denis M, Skinner MA, Koach J, de Lisle GW, Vordermeier HM, Hewinson RG, van Drunen Littel-van den Hurk S, Babiuk LA, Hecker R, Buddle BM (2005) Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone. Infect Immun 73:3540–3546PubMedGoogle Scholar
  137. Weeratna RD, Makinen SR, McCluskie MJ, Davis HL (2005) TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 23:5263–5270PubMedGoogle Scholar
  138. Wetzler LM (2010) Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity. Future Microbiol 5:749–758PubMedGoogle Scholar
  139. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA (2005a) HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci USA 102:15190–15194PubMedGoogle Scholar
  140. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA (2005b) Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol 174:7676–7683PubMedGoogle Scholar
  141. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Miles AP, Saul A, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA (2006) Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 203:1249–1258PubMedGoogle Scholar
  142. Windish HP, Duthie MS, Ireton G, Lucas E, Laurance JD, Bailor RH, Coler RN, Reed SG (2011) Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate. Vaccine 29:7842–7848PubMedGoogle Scholar
  143. Wu CC, Hayashi T, Takabayashi K, Sabet M, Smee DF, Guiney DD, Cottam HB, Carson DA (2007) Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci USA 104:3990–3995PubMedGoogle Scholar
  144. Wysocka M, Newton S, Benoit BM, Introcaso C, Hancock AS, Chehimi J, Richardson SK, Gelfand JM, Montaner LJ, Rook AH (2007) Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. Clin Lymphoma Myeloma 7:524–534PubMedGoogle Scholar
  145. Yamazaki S, Okada K, Maruyama A, Matsumoto M, Yagita H, Seya T (2011) TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One 6:e18833PubMedGoogle Scholar
  146. Zhang WW, Matlashewski G (2008) Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun 76:3777–3783PubMedGoogle Scholar
  147. Zhang L, Tian X, Zhou F (2007) Intranasal administration of CpG oligonucleotides induces mucosal and systemic Type 1 immune responses and adjuvant activity to porcine reproductive and respiratory syndrome killed virus vaccine in piglets in vivo. Int Immunopharmacol 7:1732–1740PubMedGoogle Scholar
  148. Zhang X, Chentoufi AA, Dasgupta G, Nesburn AB, Wu M, Zhu X, Carpenter D, Wechsler SL, You S, BenMohamed L (2009) A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol 2:129–143PubMedGoogle Scholar
  149. Zhang H, Liu L, Wen K, Huang J, Geng S, Shen J, Pan Z, Jiao X (2011) Chimeric flagellin expressed by Salmonella typhimurium induces an ESAT-6-specific Th1-type immune response and CTL effects following intranasal immunization. Cell Mol Immunol 8:496–501PubMedGoogle Scholar
  150. Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, Fellows-Mayle W, Storkus WJ, Walker PR, Salazar AM, Okada H (2007) Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 5:10PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  1. 1.MTS & TLR Business Development, 3M Drug Delivery Systems Division, 3M CenterSt. PaulUSA
  2. 2.TLR Agonists, Drug Delivery Systems Division, 3M CenterSt. PaulUSA

Personalised recommendations